Robin Chandra Bhattacherjee

CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT.

BioVentrix, Inc. engages in development of medical devices. It offers Less Invasive Ventricular Enhancement, or the LIVE therapy, which uses the Revivent TC transcatheter ventricular enhancement system to exclude scar tissue on the left ventricle that has occurred from a heart attack. The company was founded by Arthur A. Bertolero and Lon S. Annest in 2003 and is headquartered in San Ramon, CA.

Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom.

Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom.

Bayer HealthCare Pharmaceuticals, Inc. manufactures pharmaceutical drugs. It offers pharmaceuticals and therapeutics in the areas of diagnostic imaging, hematology and cardiology, cancer, women's health and several other chronic diseases such as multiple sclerosis and Parkinson's disease. Bayer HealthCare Pharmaceuticals was founded in 1979 and is located in Wayne, NJ.

Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland.

OM Pharma SA engages in manufacture of pharmaceutical products. Its portfolio includes products for respiratory tract infections, lower urinary tract infections, chronic venous insufficiency, microangiopathies, hemorrhoids, and menometrorrhagia. The company was founded by Jean-Rene Ricard in 1937 and is headquartered in Meyrin, Switzerland.

Interpharma Investments Ltd. operates as a holding company with interest in the distribution and manufacturing of pharmaceutical products. It provides product development, planning and procurement, and commercial manufacturing services. It also offers marketing services and support solutions to the pharmaceutical companies. The company is headquartered in Hong Kong.

Galenica AB develops and manufactures pharmaceutical drugs. It offers service to partners for the development of oral, dermal, nasal, rectal, pulmonary and parenteral formulations of small molecules to peptides/proteins and biologics. The company was founded in 1999 and is headquartered in Malmo, Sweden.

SYNLAB International GmbH offers medical laboratory services for practicing doctors, clinics and the pharmaceutical industry. It offers medical instruments, transfusion medicines, cytology, pathology, human genetics, and general hygiene services. The company was founded by Bartl Wimmer in 1998 and is headquartered in Munich, Germany.

Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom.

Soho Flordis International Pty Ltd. manufactures natural medicine products. Its brands include flordis, ProThera, COMPLEMENTARY, ginsana and KLAIRE LABS. Its products include ginsana, keenmind, nuvexa and gincosan. The company was founded in 2010 and is headquartered in St. Leonards, Australia.

Opterion Health AG is a Swiss company that focuses on bringing innovation to dialysis care and fostering home dialysis to improve the quality of life for patients suffering from end-stage renal disease (ESRD). Opterion Health is based in Muttenz, CH. The private company aims to increase the survival rates of people with ESRD and reduce healthcare costs. The company was founded in 2012 by Guido Grentzmann, and the CEO is Bjorn Englund.

Part of SynAct Pharma AB, TXP Pharma AG (Switzerland) engages in researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. The company is based in Baar, Switzerland. TXP Pharma AG (Switzerland was acquired by SynAct Pharma AB from GoodWind Holding GmbH on January 16, 2023 for $264.94 million.

Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022.